[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biovaxys Technology Corp (BVAXF)

Biovaxys Technology Corp (BVAXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0255 +562.35%
on 04/21/26
0.1690 -0.06%
on 05/14/26
+0.1245 (+280.41%)
since 04/14/26
3-Month
0.0209 +708.13%
on 04/13/26
0.1690 -0.06%
on 05/14/26
+0.0722 (+74.66%)
since 02/13/26
52-Week
0.0209 +708.13%
on 04/13/26
0.3400 -50.32%
on 05/27/25
-0.0771 (-31.34%)
since 05/14/25

Most Recent Stories

More News
Stocks in play: BioVaxys Technology Corp

Presents further validation of the Robust Immune Response from a combination of MVP-S with checkpoint ...

BVAXF : 0.1689 (+40.75%)
Stocks in play: BioVaxys Technology Corp

Announced the acceptance of an abstract related to the PESCO study, an investigator-initiated, open-label, ...

BVAXF : 0.1689 (+40.75%)
Stocks in play: BioVaxys Technology Corp

Announces today that they have entered into a Research Agreement to develop mRNA-based Rabies, Leptospirosis, ...

BVAXF : 0.1689 (+40.75%)
Stocks in play: BioVaxys Technology Corp

Announced positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) in combination ...

BVAXF : 0.1689 (+40.75%)
Stocks in play: BioVaxys Technology Corp

Announces positive preliminary results from the PESCO study, an investigator-initiated, open-label, ...

BVAXF : 0.1689 (+40.75%)
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British Columbia--(Newsfile...

BVAXF : 0.1689 (+40.75%)
BIOV.CN : 0.0700 (unch)
Stocks in play: BioVaxys Technology Corp

Announces highly promising results from a two-arm phase 1 clinical study of the safety and immunogenicity ...

BVAXF : 0.1689 (+40.75%)
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company...

BVAXF : 0.1689 (+40.75%)
BIOV.CN : 0.0700 (unch)
Stocks in play: BioVaxys Technology Corp

Provides a summary of operating initiatives over the past year following the integration of the DPXâ„¢ ...

BVAXF : 0.1689 (+40.75%)
Stocks in play: BioVaxys Technology Corp

Announces positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S") along with neoadjuvant ...

BVAXF : 0.1689 (+40.75%)

Key Turning Points

3rd Resistance Point 0.2915
2nd Resistance Point 0.2302
1st Resistance Point 0.1996
Last Price 0.1689
1st Support Level 0.1077
2nd Support Level 0.0464
3rd Support Level 0.0158

See More

52-Week High 0.3400
Fibonacci 61.8% 0.2181
Fibonacci 50% 0.1805
Last Price 0.1689
Fibonacci 38.2% 0.1428
52-Week Low 0.0209

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.